CC 90006Alternative Names: CC-90006
Latest Information Update: 20 Oct 2016
At a glance
- Originator Celgene Corporation
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 14 Oct 2016 Celgene Corporation plans a phase I trial in Healthy volunteers in USA (SC) (NCT02934269)
- 13 Oct 2016 Preclinical trials in Autoimmune disorders in USA (SC) before October 2016